Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis
December 10th 2023Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.
Read More
AI Algorithm Effectively Differentiates Between pre-PMF/ET
December 9th 2023A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.
Read More
Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.
Read More
Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.
Read More
PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL
September 7th 2023Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.
Read More
Luspatercept Displays Superiority Over ESA in RBC Transfusion-Dependent MDS
September 7th 2023The phase 3 COMMANDS trial investigating the use of luspatercept in patients with myelodysplastic syndrome who had not received an erythropoiesis-stimulating agent and were red blood cell transfusion dependent achieved its primary end point of superiority over treatment with an erythropoiesis-stimulating agent.
Read More
Tackling Resistance Mechanisms Is the Next Step in Immunotherapy Development for NSCLC
July 28th 2023Immunotherapy administered alone or in combination with chemotherapy has become the standard of care across advanced non–small cell lung cancer in several settings, with continued effort devoted to further enhancing and improving upon these treatments.
Read More
Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer
June 5th 2023The triplet combination of zotatifin, abemaciclib, and fulvestrant demonstrated a confirmed overall response rate of 21% in heavily pretreated patients with estrogen receptor–positive metastatic breast cancer.
Read More
Benefits of Neoadjuvant Nivolumab/Chemo Elucidated in NSCLC Exploratory Analysis
June 4th 2023Neoadjuvant nivolumab plus chemotherapy improved clinical outcomes vs chemotherapy alone in patients with resectable non–small cell lung cancer who received definitive surgery with numerical but not statistical improvements seen even when definitive surgery was not achieved.
Read More
The PD-1 and TIGIT bispecific rilvegostomig demonstrated promising early signs of tolerability and efficacy in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer following progression on at least 1 prior checkpoint inhibitor. according to initial findings from the phase 1/2 ARTEMIDE-01 study.
Read More
Vorasidenib Is Potential First Targeted Therapy for Low-Grade Glioma
June 4th 2023Treatment with the IDH1/2 inhibitor vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma, according to findings from the phase 3, double-blind INDIGO trial.
Read More
Teclistamab/Talquetamab Combo Shows Early Safety, Efficacy in R/R Multiple Myeloma
June 3rd 2023Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study.
Read More
Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC
June 3rd 2023The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.
Read More
Sacituzumab Govitecan Benefit Is Consistent Following CPI in Platinum-Ineligible mUC
February 17th 2023Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.
Read More
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
December 13th 2022Treatment with zanubrutinib (Brukinsa) reduced the risk of progression or death by 35% compared with ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Liso-Cel Second-Line Superiority to Standard of Care Confirmed in LBCL
December 12th 2022Second-line treatment with lisocabtagene maraleucel (liso-cel; Breyanzi) reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation for patients with high-risk relapsed/refractory large B-cell lymphoma.
Read More
Ibrutinib Induction/Maintenance Is Highly Effective for MCL
December 11th 2022The addition of ibrutinib to standard chemoimmunotherapy induction followed by autologous stem cell transplantation (ASCT) and 2 years of maintenance ibrutinib significantly improved outcomes vs standard chemoimmunotherapy induction and ASCT alone for younger patients with mantle cell lymphoma.
Read More
Pirtobrutinib Shows High Response Rates in Heavily Pretreated Waldenström Macroglobulinemia
December 11th 2022The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.
Read More
Elranatamab Shows Promise for Penta/Triple-Refractory Myeloma
December 10th 2022Treatment with the CD3/BCMA bispecific antibody elranatamab elicited an objective response rate by blinded independent central review of 61.0% in patients with penta- or triple-class refractory multiple myeloma who had not received a prior BCMA-targeted therapy.
Read More
Frontline Dostarlimab Shows Superior PFS vs Pembrolizumab in NSCLC
December 8th 2022Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer.
Read More
Sotorasib Significantly Improves PFS Vs Docetaxel for KRAS G12C–Mutated NSCLC
September 12th 2022Sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of progression or death by 34% compared with docetaxel for patients with previously treated non–small cell lung cancer with KRAS G12C mutations.
Read More
Lenvatinib/Pembrolizumab Combo Provides Continued OS, PFS Benefit in Advanced RCC
September 11th 2022Lenvatinib plus pembrolizumab showed sustained overall survival and progression-free survival benefit across poor- and intermediate-risk subgroups of patients with advanced renal cell carcinoma.
Read More